Belgium· BE-AMP-SAM110616-00
Amicla 0.1 %
A amcinonide product containing amcinonide, registered in Belgium by BePharBel Manufacturing. The same ATC class is registered in 4 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Amcinonide is registered in 4 of 19 countries.
Countries holding a registration under ATC D07AC11 (amcinonide), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 2 of them publish a price we can compare per daily dose
Amcinonide · ATC D07AC11
4 / 19 countries
- Belgiumprice
- Canada
- Japan
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Amcinonide
- Manufacturer
- BePharBel Manufacturing
- Country
- Belgium (BE)
- ATC code
- D07AC11
- ATC class
- Amcinonide
- Defined daily dose
- 1.5 mg, T
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb0854158
- be_apb0700666
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
55 interactions on record for amcinonide.
Graded by severity as the source publishes them — 55 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Amcinonide · interactions on record
55 records
Same medicine, other countries
Amcinonide in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Luxembourg · Amicla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/75ad47ff-2432-4979-8e7e-19e4f8b6a969 GET /v1/drugs/75ad47ff-2432-4979-8e7e-19e4f8b6a969?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Cream",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Amicla 0.1 %",
"name_fr": "Amicla 0.1 %",
"name_nl": "Amicla 0.1 %",
"amp_code": "SAM110616-00",
"strengths": [
"1.0000",
"21.0000",
"40.0000",
"35.0000"
],
"pack_count": 3,
"substances": [
"Amcinonide",
"Benzyl Alcohol",
"Glycerol",
"Sorbitol"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Amcinonide",
"authorisation_numbers": [
"BE110616"
]
}See everything about amcinonide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.